Remke, M
~ 300  Ergebnisse:
Personensuche X
?
1

P10.07.A A CLINICALLY COMPATIBLEIN VITRODRUG-SCREENING PLAT..:

Jeising, S ; Trübel, J ; Felsberg, J...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii63-ii63 , 2023
 
?
3

Longitudinal stability of molecular alterations and drug re..:

Nickel, A.C. ; Picard, D. ; Qin, N....
Biomedicine & Pharmacotherapy.  144 (2021)  - p. 112278 , 2021
 
?
4

C.5 Musashi-1 is a master regulator of aberrant translation..:

Kameda-Smith, MM ; Zhu, H ; Luo, E...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  48 (2021)  s3 - p. S19-S19 , 2021
 
?
5

18 Peroxiredoxin1 is a therapeutic target in group-3 medull..:

Sajesh, BV. ; Ngoc, OH. ; Omar, R....
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  45 (2018)  S3 - p. S16-S16 , 2018
 
?
6

CBF1 is clinically prognostic and serves as a target to blo..:

Maciaczyk, D ; Picard, D ; Zhao, L...
British Journal of Cancer.  117 (2017)  1 - p. 102-112 , 2017
 
?
 
?
11

MB-18 * POST-TRANSLATIONAL REGULATION OF ATOH1: FROM CEREBE..:

Cigna, S. M. ; Forget, A. ; Bihannic, L....
Neuro-Oncology.  17 (2015)  suppl 3 - p. iii23-iii23 , 2015
 
?
12

MB-02 * SONIC HEDGEHOG INDUCES YB-1 IN A YAP-DEPENDENT MANN..:

Dey, A. ; Robitaille, M. ; Remke, M....
Neuro-Oncology.  17 (2015)  suppl 3 - p. iii20-iii20 , 2015
 
?
 
?
 
?
15

MB-03 * FUNCTIONAL CHARACTERIZATION OF NOVEL BIOMARKERS IN ..:

Liang, L. ; Aiken, C. ; McClelland, R....
Neuro-Oncology.  17 (2015)  suppl 3 - p. iii20-iii20 , 2015
 
1-15
Mehr Literatur finden